Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 752930, 9 pages
http://dx.doi.org/10.1155/2015/752930
Research Article

Evaluation of the Efficacy of a Bacteriophage in the Treatment of Pneumonia Induced by Multidrug Resistance Klebsiella pneumoniae in Mice

1School of Life Science and Biotechnology, Dalian University of Technology, Dalian 116024, China
2Orthopedics Research Center, Affiliated Zhongshan Hospital of Dalian University, Dalian 116001, China
3Ministry of Education Center for Food Safety of Animal Origin, Dalian University of Technology, Dalian 116620, China

Received 31 October 2014; Revised 19 January 2015; Accepted 4 March 2015

Academic Editor: Teresa M. Coque

Copyright © 2015 Fang Cao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Hackstein, S. Kranz, A. Lippitsch et al., “Modulation of respiratory dendritic cells during Klebsiella pneumonia infection,” Respiratory Research, vol. 14, no. 1, article 91, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Podschun and U. Ullmann, “Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors,” Clinical Microbiology Reviews, vol. 11, no. 4, pp. 589–603, 1998. View at Google Scholar · View at Scopus
  3. S. J. Cryz, “Progress in immunization against Klebsiella infections,” European Journal of Clinical Microbiology, vol. 2, no. 6, pp. 523–528, 1983. View at Publisher · View at Google Scholar · View at Scopus
  4. J. M. Zhu, R. J. Jiang, H. S. Kong et al., “Emergence of novel variants of gyrA, parC, qnrS genes in multi-drug resistant Klebsiella caused pneumonia,” Zhonghua Liu Xing Bing Xue Za Zhi, vol. 34, pp. 61–66, 2013. View at Google Scholar
  5. D. K. Pomakova, C.-B. Hsiao, J. M. Beanan et al., “Clinical and phenotypic differences between classic and hypervirulent Klebsiella pneumonia: an emerging and under-recognized pathogenic variant,” European Journal of Clinical Microbiology & Infectious Diseases, vol. 31, no. 6, pp. 981–989, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Shoma, M. Kamruzzaman, A. N. Ginn, J. R. Iredell, and S. R. Partridge, “Characterization of multidrug-resistant Klebsiella pneumoniae from Australia carrying blaNDM-1,” Diagnostic Microbiology and Infectious Disease, vol. 78, no. 1, pp. 93–97, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Demirdag and S. Hosoglu, “Epidemiology and risk factors for ESBL-producing Klebsiella pneumoniae: a case control study,” Journal of Infection in Developing Countries, vol. 4, no. 11, pp. 717–722, 2010. View at Google Scholar · View at Scopus
  8. E. B. Hirsch and V. H. Tam, “Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection,” Journal of Antimicrobial Chemotherapy, vol. 65, no. 6, pp. 1119–1125, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Chhibber, S. Kaur, and S. Kumari, “Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice,” Journal of Medical Microbiology, vol. 57, no. 12, pp. 1508–1513, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. J. J. Hilliard, J. L. Melton, L. Hall et al., “Comparative effects of carbapenems on bacterial load and host immune response in a Klebsiella pneumoniae murine pneumonia model,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 2, pp. 836–844, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Pouillot, M. Chomton, H. Blois et al., “Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b: H4-ST131 Escherichia coli strain producing CTX-M-15,” Antimicrobial Agents and Chemotherapy, vol. 56, no. 7, pp. 3568–3575, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Biswas, S. Adhya, P. Washart et al., “Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium,” Infection and Immunity, vol. 70, no. 1, pp. 204–210, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Gu, X. Liu, Y. Li et al., “A method for generation phage cocktail with great therapeutic potential,” PLoS ONE, vol. 7, no. 3, Article ID e31698, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Capparelli, M. Parlato, G. Borriello, P. Salvatore, and D. Iannelli, “Experimental phage therapy against Staphylococcus aureus in mice,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 8, pp. 2765–2773, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Kutter, D. de Vos, G. Gvasalia et al., “Phage therapy in clinical practice: treatment of human infections,” Current Pharmaceutical Biotechnology, vol. 11, no. 1, pp. 69–86, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Brüssow, “What is needed for phage therapy to become a reality in Western medicine?” Virology, vol. 434, no. 2, pp. 138–142, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. B. K. Chan, S. T. Abedon, and C. Loc-Carrillo, “Phage cocktails and the future of phage therapy,” Future Microbiology, vol. 8, no. 6, pp. 769–783, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. E. L. Ellis and M. Delbruck, “The growth of bacteriophage,” The Journal of General Physiology, vol. 22, pp. 365–384, 1939. View at Google Scholar
  19. F. Okada, Y. Ando, K. Honda et al., “Acute Klebsiella pneumoniae pneumonia alone and with concurrent infection: comparison of clinical and thin-section CT findings,” British Journal of Radiology, vol. 83, no. 994, pp. 854–860, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. C. H. Lester, S. S. Olsen, L. Jakobsen et al., “Emergence of extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae in Danish hospitals; This is in part explained by spread of two CTX-M-15 clones with multilocus sequence types 15 and 16 in Zealand,” International Journal of Antimicrobial Agents, vol. 38, no. 2, pp. 180–182, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Adler, E. Khabra, I. Chmelnitsky et al., “Development and validation of a multiplex PCR assay for identification of the epidemic ST-258/512 KPC-producing Klebsiella pneumoniae clone,” Diagnostic Microbiology & Infectious Disease, vol. 78, no. 1, pp. 12–15, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Ambretti, P. Gaibani, F. Caroli, L. Miragliotta, and V. Sambri, “A carbapenem-resistant Klebsiella pneumoniae isolate harboring KPC-I from Italy,” New Microbiologica, vol. 33, no. 3, pp. 281–282, 2010. View at Google Scholar · View at Scopus
  23. X. Wittebole, S. de Roock, and S. M. Opal, “A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens,” Virulence, vol. 5, no. 1, pp. 226–235, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. D. R. Harper and M. C. Enright, “Bacteriophages for the treatment of Pseudomonas aeruginosa infections,” Journal of Applied Microbiology, vol. 111, no. 1, pp. 1–7, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Kim and S. Ryu, “Characterization of a T5-like coliphage, SPC35, and differential development of resistance to SPC35 in Salmonella enterica serovar typhimurium and Escherichia coli,” Applied and Environmental Microbiology, vol. 77, no. 6, pp. 2042–2050, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Skurnik and E. Strauch, “Phage therapy: facts and fiction,” International Journal of Medical Microbiology, vol. 296, no. 1, pp. 5–14, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Matsuzaki, M. Yasuda, H. Nishikawa et al., “Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage φMR11,” Journal of Infectious Diseases, vol. 187, no. 4, pp. 613–624, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Morello, E. Saussereau, D. Maura, M. Huerre, L. Touqui, and L. Debarbieux, “Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: First steps towards treatment and prevention,” PLoS ONE, vol. 6, no. 2, Article ID e16963, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Bordon, S. Aliberti, R. Fernandez-Botran et al., “Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia,” International Journal of Infectious Diseases, vol. 17, no. 2, pp. e76–e83, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Zimecki, J. Artym, M. Kocięba, B. Weber-Da̧browska, J. Borysowski, and A. Gárski, “Effects of prophylactic administration of bacteriophages to immunosuppressed mice infected with Staphylococcus aureus,” BMC Microbiology, vol. 9, article 169, 2009. View at Publisher · View at Google Scholar · View at Scopus